Dabocemagene autoficel API Manufacturers
compare suppliers & get competitive offers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Dabocemagene autoficel is listed?
Join our notification list by following this page.
Join our notification list by following this page.
List your company
Are you a supplier of Dabocemagene autoficel or other APIs and are you looking to list your company on Pharmaoffer?
Click the button below to find out more
Click the button below to find out more
Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?
Click the button below to switch over to the contract services area of Pharmaoffer.
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Dabocemagene autoficel API 2365353-63-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Dabocemagene autoficel. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Dabocemagene autoficel
- Synonyms:
- AUTOLOGOUS HUMAN DERMAL FIBROBLAST CELLS DERIVED FROM SKIN BIOPSIES, AND TRANSDUCED WITH A NON-REPLICATING, SELF-INACTIVATING LENTIVIRUS VECTOR THAT ENCODES HUMAN COLLAGEN TYPE VII ALPHA 1 (COL7A1) UNDER THE CONTROL OF A HUMAN CYTOMEGALOVIRUS (CMV) PROMO , D-Fi , DNA (RECOMBINANT LENTIVIRUS VECTOR INXN-2004-TRANSDUCED HUMAN AUTOLOGOUS DYSTROPHIC EPIDERMOLYSIS BULLOSA DERMAL FIBROBLAST CELL FCX-007 INTEGRATED PROVIRAL HUMAN COLLAGEN TYPE VII TRANSGENE COL7A1 PLUS 5'-HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/PO
- Cas Number:
- 2365353-63-3
- DrugBank number:
- DB17878
- Unique Ingredient Identifier:
- 0S9A4XK1WT
General Description:
Dabocemagene autoficel, identified by CAS number 2365353-63-3, is a notable compound with significant therapeutic applications. Dabocemagene autoficel is an _ex vivo_, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen. Developed by Castle Creek Biosciences Inc, dabocemagene autoficel is being investigated for the treatment of dystrophic epidermolysis bullosa.
